Clinical Trial Update: A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating palifermin for reducing oral mucositis in patients with advanced head and neck cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• Kepivance (Palifermin)

Snippet

Sponsor: Amgen | Conditions: Head and Neck Cancer | Phase 3 | Status: COMPLETED